Speakers
The final program is soon available. It will include academic speakers with leading expertise in CETSA development, as well as representatives from companies such as Astra Zeneca, Sprint Bioscience, Medivir, GlaxoSmithKline, Cellzome - a GSK company, Bayer, MSD, Cisbio and CBCS.
Dr. Thomas Lundbäck, AstraZeneca-Gothenburg
“In Cell Kinetics of Drug Binding: Towards a Mechanistic Understanding and Quantitative Interpretation of CETSA data”
- EMBL, Genome Biology
Adam Schwaid, MSD
“Application of 2D Thermal Protein Profiling for Antimicrobial Target ID”
Marc Holbert, GlaxoSmithKline
”Revving up CETSA: Can we replace cellular mechanistic assays in early drug discovery?”
Jessica Perrin, Cellzome – A GSK company
“Thermal proteome profiling in drug discovery”
Jörg Weiske, Bayer
"CETSA @ Bayer AG – Case study MTH1"
Biljana Rizoska, Medivir
”Cathepsin S target engagement in human cells using CETSA”
Davide Gianni, Astra Zeneca
“CETSA® in Astrazeneca”
Joe Shaw, Astra Zeneca
“CETSA HT to determine direct binders of the Androgen Receptor”
Hanna Axelsson and Helena Almqvist, CBCS
“Development of high throughput CETSA assays - experiences from four years in the lab”
Delphine Jaga, Cisbio
”CETSA & HTRF® a good combination to study intracellular proteins”
Andrew Zhang, AstraZeneca
"Application of CETSA to study target engagement on membrane proteins and multipass transmembrane receptors"
Martin Andersson, Sprint Bioscience
"Properties of thermal shift assays and implications for assay development in CETSA"
Teemu Miettinen, MIT
"Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib"